


H2L 5765834

Cat. No.:	HY-15706		
CAS No.:	420841-84-5		
Molecular Formula:	C ₂₁ H ₁₂ N ₂ O ₇		
Molecular Weight:	404.33		
Target:	LPL Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (618.31 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.4732 mL	12.3661 mL	24.7323 mL
5 mM	0.4946 mL	2.4732 mL	4.9465 mL
10 mM	0.2473 mL	1.2366 mL	2.4732 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, LPA₃, and LPA₅, with IC₅₀s of 94, 752, and 463 nM respectively^[1].

IC₅₀ & Target

LPA ₁ Receptor 94 nM (IC ₅₀)	LPA ₃ Receptor 752 nM (IC ₅₀)	LPA ₅ Receptor 463 nM (IC ₅₀)
--	---	---

In Vitro

H2L 5765834 displays no effect on LPA₂ or LPA₄ receptors^[1].
 H2L 5765834 inhibits LPA-induced platelet shape change with an IC₅₀ of 13.73±2.52 μM^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

H2L 5765834 (20 mg/kg; i.p.) could not affect the LPA-induced decrease of alanine transaminase (ALT) in the acetaminophen (APAP) overdose-induced acute liver injury model^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Williams JR, et, al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19; 284(25): 17304-19.

[2]. Bae GH, et, al. Lysophosphatidic acid protects against acetaminophen-induced acute liver injury. Exp Mol Med. 2017 Dec 8; 49(12): e407.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA